{"entity":{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","aka":[],"tldr":"After hamster cells have grown an antibody drug, the antibody has to be fished out of a soup of cells, DNA and viruses and made pure enough to inject. Purification is where much of the cost and many of the bottlenecks of biologics sit.","summary":"Downstream processing takes the harvested cell culture fluid from a CHO bioreactor and turns it into bulk drug substance. The harvest is clarified by centrifugation and depth filtration, captured on a Protein A affinity column that binds the antibody's Fc region and lets everything else through, held at low pH to inactivate enveloped viruses, polished on ion exchange and mixed-mode columns to strip host-cell proteins, DNA and aggregates, passed through a virus-retaining nanofilter, and concentrated and buffer-exchanged by ultrafiltration and diafiltration before sterile filtration. Regulators require validated viral clearance of several orders of magnitude across the steps, and every batch is tested for host-cell protein, DNA, aggregates, charge variants and glycan pattern.\n\nProtein A resin is the single most expensive consumable in antibody manufacture and is supplied by a small number of makers (Cytiva, Merck KGaA's life science arm, Thermo Fisher, Purolite and Tosoh among them), and column and membrane capacity, not bioreactor volume, often sets how fast a plant can run as titres rise. Continuous and multi-column chromatography, membrane adsorbers and precipitation are the current efficiency frontier. Antibody-drug conjugates repeat parts of this chain after conjugation to remove free payload.","status":"standard-of-care","asOf":"2026-09-17","links":[{"label":"ICH Q5A: viral safety evaluation of biotechnology products","url":"https://www.ich.org/page/quality-guidelines"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Protein_A"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":["monoclonal-antibody-manufacturing","single-use-bioprocessing","sterile-fill-finish","adc-cdmo-manufacturing","biosimilar-manufacturing","monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":["pembrolizumab","nivolumab","trastuzumab","rituximab","bevacizumab"],"companies":["cytiva","sartorius","thermo-fisher","merck-kgaa","samsung-biologics","lonza","wuxi-biologics","fujifilm-diosynth","boehringer-ingelheim-biox"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo manufacturing expansion","editedOn":"2026-09-17"},"principle":"Sequential capture, viral inactivation and polishing steps exploit affinity, charge and size to reach injectable purity with validated viral safety.","strengths":["Platform process reused across antibodies","Validated viral safety","Resins reusable for hundreds of cycles"],"limitations":["Protein A resin cost and supplier concentration","Downstream capacity lags rising titres","Each new format (bispecific, ADC) needs process redevelopment"],"since":1990},"route":"/technologies/downstream-purification-chromatography/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/"},{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/"},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/"},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/"},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/"},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/"},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/"},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/"},{"id":"sartorius","kind":"company","name":"Sartorius","route":"/companies/sartorius/"},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/"},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/"}]}}